News

Press Releases

July 13, 2023

Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial

May 17, 2023

EUROPCR 2023: LATE-BREAKING CLINICAL DATA DEMONSTRATE ELIXIR MEDICAL’S DYNAMX BIOADAPTOR RESTORES VESSEL MOTION AND FUNCTION WITH BETTER EFFECTIVENESS AT 12 MONTHS COMPARED TO A LEADING DRUG-ELUTING STENT (DES)

May 2, 2023

ELIXIR MEDICAL TO ANNOUNCE LATE-BREAKING CLINICAL DATA AT EUROPCR 2023 SESSION FEATURING WORLD’S FIRST TRANSFORMING CORONARY ARTERY IMPLANT DESIGNED TO RESTORE VESSEL PHYSIOLOGY AND FUNCTION

1 2 3 4 ›»

July 13, 2023

Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial

May 17, 2023

EUROPCR 2023: LATE-BREAKING CLINICAL DATA DEMONSTRATE ELIXIR MEDICAL’S DYNAMX BIOADAPTOR RESTORES VESSEL MOTION AND FUNCTION WITH BETTER EFFECTIVENESS AT 12 MONTHS COMPARED TO A LEADING DRUG-ELUTING STENT (DES)

May 2, 2023

ELIXIR MEDICAL TO ANNOUNCE LATE-BREAKING CLINICAL DATA AT EUROPCR 2023 SESSION FEATURING WORLD’S FIRST TRANSFORMING CORONARY ARTERY IMPLANT DESIGNED TO RESTORE VESSEL PHYSIOLOGY AND FUNCTION

1 2 3 4 ›»

Media Coverage

April 2021

Medtech Insight

Start-Up Spotlight: Elixir Works to ‘Uncage’ The Coronary After Intervention

June 2020

TCTMD/The Heartbeat

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

Cardiovascular News

PCR e-Course 2020: DynamX Bioadaptor shows “excellent” safety and efficacy at 12 months

Media Resources

Media contact:

Email to PR@ElixirMedical.com

DynamX transparent

3300 px x 875 px
PNG

DynamX Blue Background

3840 px x 2160 px
PNG

DynamX Alone

1920 x 1080
MP4

DynamX In Vessel

1920 x 1080
MP4

News

Press Releases

Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial

EUROPCR 2023: LATE-BREAKING CLINICAL DATA DEMONSTRATE ELIXIR MEDICAL’S DYNAMX BIOADAPTOR RESTORES VESSEL MOTION AND FUNCTION WITH BETTER EFFECTIVENESS AT 12 MONTHS COMPARED TO A LEADING DRUG-ELUTING STENT (DES)

ELIXIR MEDICAL TO ANNOUNCE LATE-BREAKING CLINICAL DATA AT EUROPCR 2023 SESSION FEATURING WORLD’S FIRST TRANSFORMING CORONARY ARTERY IMPLANT DESIGNED TO RESTORE VESSEL PHYSIOLOGY AND FUNCTION

Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial

EUROPCR 2023: LATE-BREAKING CLINICAL DATA DEMONSTRATE ELIXIR MEDICAL’S DYNAMX BIOADAPTOR RESTORES VESSEL MOTION AND FUNCTION WITH BETTER EFFECTIVENESS AT 12 MONTHS COMPARED TO A LEADING DRUG-ELUTING STENT (DES)

ELIXIR MEDICAL TO ANNOUNCE LATE-BREAKING CLINICAL DATA AT EUROPCR 2023 SESSION FEATURING WORLD’S FIRST TRANSFORMING CORONARY ARTERY IMPLANT DESIGNED TO RESTORE VESSEL PHYSIOLOGY AND FUNCTION

Media Coverage

April 2021

Medtech Insight

June 2020

TCTMD/The Heartbeat

Cardiovascular News

Media Resources

Media contact:

DynamX transparent

DynamX Blue Background

DynamX Alone

DynamX In Vessel

PMN 574 Rev A

Elixir, Innovation for Life and DESyne are registered trademarks, and DynamX a trademark, in the US and internationally for Elixir Medical Corporation.

DynamX Coronary Bioadaptor System and DESyne X2 Novolimus Eluting Coronary Stent System are CE Mark approved.

©2022 Elixir Medical. All rights reserved.

Site designed by The Deciding Factor, Inc.